ArticleShock (Augusta, Ga.)2025
METHANE ADMINISTRATION DURING OXYGENATION MITIGATES ACUTE KIDNEY INJURY IN A PIG MODEL OF 24-H VENO-VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION.
Article in Shock (Augusta, Ga.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Time Matters: Methane Inhalation Mitigates Mitochondrial and Organ Dysfunction in Advanced Experimental Sepsis.Antioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBackground: Severe respiratory failure often requires veno-venous extracorporeal membrane oxygenation (v-v ECMO) treatment, a procedure frequently associated with acute kidney injury (AKI). Preclinical studies have demonstrated the anti-inflammatory properties of inhaled methane (CH 4 ). This experimental protocol aimed to investigate whether CH 4 gas administration could mitigate the development of AKI in a clinically relevant large animal model of v-v ECMO. Methods: Anesthetized miniature pigs were divided into three groups (n = 6 each). Following cannulation of the right femoral and internal jugular veins, v-v ECMO was initiated and maintained for 24 h, followed by a 6-h post-ECMO observation. The control group underwent cannulation without ECMO, while the v-v ECMO+CH 4 group received a 2% CH 4 -air mixture via the oxygenator. Urine output was recorded, and kidney injury was assessed using plasma and urine neutrophil gelatinase-associated lipocalin levels. Inflammatory activation was evaluated through plasma interleukin-1β (IL-1β) and interleukin-8 (IL-8) levels. Kidney tissue samples were analyzed for histopathological changes, xanthine oxidoreductase and myeloperoxidase activities, and nitrite/nitrate levels. Results: The CH 4 -treated group exhibited significantly higher post-ECMO renal arterial flow (244.7 ± 70 vs. 96.3 ± 21 mL/min) and increased average urine output (5.75 ± 1.6 vs. 3.25 ± 0.4 mL/h/kg) compared to the v-v ECMO group. CH 4 administration reduced urine and plasma neutrophil gelatinase-associated lipocalin levels and demonstrated lower histological damage scores (0.8 ± 0.3 vs. 3.3 ± 0.8). Furthermore, CH 4 treatment decreased xanthine oxidoreductase and myeloperoxidase activities and reduced inflammatory mediators, including IL-1β, IL-8, and nitrite/nitrate. Conclusion: CH 4 admixture significantly mitigates inflammatory activation and renal injury associated with v-v ECMO. These findings suggest that CH 4 may serve as an effective adjunctive means to reduce renal complications of v-v ECMO therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.